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Hydrochlorothiazide exerts no direct 
vasoactivity in the human forearm
Peter Pickkers*, Frans G.M. Russel*, 
Alun D. Hughest, Theo Thien* and Paul Smits*
Background: Recently, hydrochlorothiazide has been shown to relax vascular 
smooth muscle in vitro in clinically relevant concentrations by the opening of 
calcium-activated potassium channels, leading to hyperpolarization and consequent 
closing of voltage-operated calcium channels. Long-term administration of hydro­
chlorothiazide reduces peripheral vascular resistance in vivo in man. These results 
indicate that hydrochlorothiazide has hemodynamic activity, and we therefore 
examined the direct vascular action of this drug in vivo.
Subjects and methods: Forearm vasodilator responses to the infusion of a placebo and 
five increasing doses of hydrochlorothiazide into the brachial artery were recorded 
by venous occlusion strain-gauge plethysmography (perfused forearm technique) in 
eight normotensive male volunteers. Venous samples were taken from an ipsilateral 
antecubital vein at the end of each infusion period to measure the hydrochlorothiazide 
concentration.
Results and discussion: Plasma concentrations of hydrochlorothiazide averaged 
3.5±0,3jug/ml at the highest infusion rate. This concentration leads to a 60±10% 
relaxation in vitro and is more than 10 times the therapeutic plasma concentration. 
Despite these supratherapeutic levels, we were unable to demonstrate a change 
in forearm blood flow and vascular resistance. Also, no significant changes were 
observed in blood pressure and heart rate.
Conclusion: In contrast to in vitro results, hydrochlorothiazide does not exert 
any direct vasoactivity in the forearm vascular bed of healthy normotensive male 
volunteers at (supra)therapeutic plasma concentrations.
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Introduction
Thiazide diurctics are widely used and considered 
treatment o f first choice in most patients with essential 
hypertension as they reduce the risk of stroke and 
other cardiovascular events [1]. Evidence is accumu­
lating that their efficacy is at least partly due to a 
direct hemodynamic action. During chronic thiazide 
administration, the plasma volume returns to baseline 
and peripheral resistance decreases [2 ], suggesting a 
vascular action besides the diuretic effects. Chronic 
treatment with thiazides has also been reported to reduce
the vasoconstrictor action o f norepinephrine in both 
normotensives and hypertensive patients [3,4]. An acute 
diuretic-induced fall in blood pressure is incidentally 
observed, dissociated from changes in plasma volume 
in patients with renal failure [5], although there are no 
consistent data.
In animals, parenterally administered hydrochlorothiazide 
causes an immediate fall in blood pressure associated 
with inhibition o f the vasopressor response to stimu­
lation o f adrenergic vasomotor fibers, while prolonged 
treatment with hydrochlorothiazide in rabbits and dogs
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has been reported to inhibit norepinephrine-induced 
vasoconstriction both in vivo and in vitro [6 ].
In the past few years concentration-dependent relaxant 
effects o f  clinically relevant concentrations o f hydro­
chlorothiazide have been demonstrated in human and 
guinea-pig isolated resistance arteries [7]. This vasodila­
tor activity is associated with a fall in intracellular Ca-+ 
[8 ]. Its action is inhibited by charybdotoxin, a blocker o f  
large-conductance Ca2+-activated K+channels but not 
by glibenclamide, a blocker of ATP-sensitive K+channels 
[7]. In summary, it seems that hydrochlorothiazide 
increases the permeability o f smooth muscle membranes 
to K+ [9], probably by opening Ca2+-activated K+ 
channels, thereby leading to K+ efflux [10] and 
membrane hyperpolarization, and consequent closing 
o f voltage-operated Ca2+ channels and smooth muscle 
relaxation.
The present study was aimed at investigating the putative 
direct vascular effects of hydrochlorothiazide in humans 
in vivo.
Subjects and methods
The study protocol was approved by the Ethics Com­
mittee o f our hospital and informed written consent 
was obtained from each subject before participation. 
Eight healthy male volunteers were submitted to 
clinical examination before admission to the study. 
None o f  the subjects smoked or was on any kind 
o f medication. The age, weight, height, body mass 
index, forearm volume and systolic/diastolic blood 
pressure of these subjects were, respectively, 24,8 ± 5 .0  
years, 78.5 ± 4 .7  kg, 186.0±5.0 cm, 2 2 .7 ±  1.6 kg/m 2, 
1088 ±  133 ml and 127± 9 /73± 9m m H g. The subjects
were instructed to follow their usual diets, but to abstain 
from chocolate and alcohol and caffeine-containing 
beverages 24 h preceding the experiment.
The experiments were performed during a 3-h immo­
bilization period in the supine position in a quiet and 
temperature-controlled laboratory as descibed previously
[11]. Briefly, the left brachial artery was cannulated 
for drug infusion and blood pressure monitoring. After 
occlusion o f the hand circulation, forearm blood flow 
was measured in both arms with venous occlusion 
plethysmography using mercury-in-silastic strain gauges. 
The forearm blood flow of the contralateral arm was 
used as a time-control value so that systemic effects could 
be observed and vasoactive effects could be expressed 
as a quotient of the left and right arm [12]. Each 
infusion period lasted lOmin and was alternated with a 
1 0 -min pause during which the wrist cuff was deflated 
to allow recovery o f the hand circulation. In four subjects 
the highest dose of hydrochlorothiazide was infused for
2 0 min instead o f lOmin. On the ipsilateral side an 
antecubital vein was cannulated for blood sampling.
On the day o f each experiment hydrochlorothiazide 
was reconstituted from a sterile powder, diluted in
1.4% sodium bicarbonate (pH 7.4) to a concentration 
of 0 . 1  mg/ml and passed through a 0 .2 2 -jim Millipore 
(Milford, Massachusetts, USA) filter. Further dilutions 
were prepared immediately before the experiment. 
Consequently, 1.4% sodium bicarbonate was used during 
the placebo infusion period.
The experiment started with a single-blind infusion of 
placebo, and then the diuretic was infused for 1 0  min 
at each of five increasing rates (0.1, 0.3, 1.0, 3.0 and 
10.0 |X g/min per 100 ml forearm tissue). During the last 
minute of each infusion period o f 1 0  min, an ipsilateral 
venous blood sample was taken and plasma diuretic 
concentrations were measured by chromatography [13].
Statistics
All data are expressed as means ±SEM . Forearm blood 
flows were averaged from the last 8  min o f  each infusion 
period. Ratios o f forearm blood flow were calculated by 
dividing the ipsilateral by the contralateral forearm blood
flow.
Analysis o f variance for repeated measures was used to 
test for differences in forearm blood flow during the 




Ratios of infused to control forearm blood flow and 
ipsilateral venous plasma concentrations o f hydrochloro­
thiazide are shown in Fig. 1. During five increasing 
doses of hydrochlorothiazide there was no significant 
effect on forearm blood flow compared to the placebo 
infusion. Using the data from the last 2 min o f infusion 
(instead of the last 8  min) did not change these results. 
The vascular resistance (quotient o f  blood pressure and 
forearm blood flow) o f the hydrochlorothiazide-infused 
forearm averaged 68.7 ± 6.5 AU during placebo, rising 
to 8 6 . 6  ±9 .2  AU at the highest dose (NS). Regional 
hydrochlorothiazide plasma concentrations ranged from
0.04 + 0.003 at the lowest dose to 3.5 ± 0 ,3  (ig/ml 
(comparable to 10 |LLmol/l) at the highest dose. The 
hydrochlorothiazide infusion o f 2 0  min in four subjects 
showed no significant effects on forearm blood flow or 
vascular resistance.
Intra-arterial blood pressure and heart rate (respectively 
1 2 4 ± 4 /6 4 ± 2 m n iH g  and 58 ± 2  beats/min during the 
placebo and 128 ±  4 /67  ±  2 and 58 ±  3 during the highest 
hydrochlorothiazide dose) did not change significantly 
during the experiments.
Ratio Forearm Blood Flow [HCTZ] lasm.
f'g- l • Ratio of forearm blood flow in hydrochlorothiazide 
(HCTZ)-infused to control arm as measured by venous oc­
clusion plethysmography (left axis) and local venous hydro­
chlorothiazide concentrations during an intra-arterial infu­
sion of placebo and five increasing doses of hydrochloro­
thiazide (right axis). Values are expressed as means±SEM 
(n = 8).
Discussion
In contrast to in vitro experiments by our group [8 ] 
and others [7,9,10], and studies on vasoactivity after 
long-term systemic administration [2-4], the present 
study showed that the intra-arterial administration o f  
hydrochlorothiazide exerted no direct effects on the 
forearm vascular bed o f male normotensive volunteers. 
As expected with this technique, there were no blood 
pressure or heart rate changes during the experiments 
to suggest any acute effect. So, despite considerable evi­
dence that hydrochlorothiazide exerts direct vasoactivity, 
our in vivo findings suggest that in pharmacologically rel­
evant concentrations hydrochlorothiazide is not directly 
vasoactive in the forearm vascular bed.
At the highest infusion rate, the mean plasma con­
centration reached 3 .5 ± 0 .3  jig/m l (~10 p.mol/1). This 
concentration resulted in a 60 ± 1 0 % vasodilation in 
vitro o f  human subcutaneous resistance vessels [7] and 
was 10-30  times the therapeutic plasma concentration 
in subjects with normal renal function [14]. The 
protein-bound fraction was not measured, but was 
expected to be in the normal range o f 22% [15] to 55%
[16]. Thus, even after correction for the protein-bound 
fraction, the drug concentration remained well above 
therapeutic levels.
There are a number o f potential explanations for this 
discrepancy between our in vitro and in vivo results. First, 
the in vitro experiments were performed on resistance 
arteries from subcutaneous fat or the mesenteric vascular 
bed. In contrast, the current in vivo experiments pre­
dominantly refer to resistance arteries o f skeletal muscle. 
Second; during in vitro experiments, hydrochlorothiazide 
can gain access to the outside o f  the vessel, allowing
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direct exposure o f the drug to the vascular smooth 
muscle cell, instead of the physiological condition o f  
exposure from the inside o f the vessel to the endothelium 
as in the perfused forearm technique. Apart from being 
an anatomical barrier, the endothelium is important in 
modulating vascular tone, which could be o f significant 
importance. The possibility that hydrochlorothiazide 
may influence Ca2+-activated K+ channels in endothelial 
cells as well as vascular smooth muscle cells and so affect 
endothelial modulation o f tone cannot be excluded.
Third, it has been established previously [3,4] that //; 
vivo chronic chlorothiazide administration attenuated the 
vasoconstrictor response of forearm vessels to nora­
drenaline. Therefore, the mechanism o f  thiazide-induced 
vasodilation in vivo might be a drug-induced reduction 
in the effect of endogenous vasoconstrictor influences, 
such as norepinephrine, angiotensin II or sympathetic 
nervous tone. In patients with essential hypertension, 
who are known to have an increased vascular reactivity, 
the vascular effects of hydrochlorothiazide might be 
more pronounced than in normotensive subjects. This 
suggestion is in accordance with observations that 
the antihypertensive action o f hydrochlorothiazide is 
related to the severity o f the hypertension. This implies 
that hydrochlorothiazide has no hypotensive action in 
normotensive subjects [17] and may therefore exert no 
vascular action in these subjects.
In conclusion, in contrast to our in vitro observations, 
hydrochlorothiazide did not have a direct vasorelaxant 
effect in skeletal muscles in vivo in normotensive subjects.
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